Details for Patent: 10,646,480
✉ Email this page to a colleague
Which drugs does patent 10,646,480 protect, and when does it expire?
Patent 10,646,480 protects NUPLAZID and is included in one NDA.
Protection for NUPLAZID has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has two patent family members in two countries.
Summary for Patent: 10,646,480
| Title: | Formulations of pimavanserin |
| Abstract: | Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin. |
| Inventor(s): | Ravi Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti |
| Assignee: | Acadia Pharmaceuticals Inc |
| Application Number: | US16/571,554 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,646,480 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Delivery; Device; Dosage form; |
Drugs Protected by US Patent 10,646,480
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | CAPSULE;ORAL | 210793-001 | Jun 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,646,480
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Sweden | 1730232 | Sep 1, 2017 |
International Family Members for US Patent 10,646,480
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3675827 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2019046167 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
